Korsana Biosciences KRSA

Cyclerion Therapeutics Inc is a biopharmaceutical company that concentrates on developing new treatments for serious neuropsychiatric disorders. The firm was incorporated in 2018 and maintains its headquarters in Cambridge Massachusetts. Its primary focus is on a candidate called CYC 126 which is being studied as a potential therapy for treatment resistant depression. In addition Cyclerion continues to manage a portfolio of legacy soluble guanylate cyclase assets that it seeks to monetize through licensing or other strategic transactions. The company aims to build a pipeline that addresses conditions with high unmet medical need while leveraging existing scientific knowledge and safety data.

Cyclerion currently generates revenue mainly from licensing agreements and milestone payments associated with its sGC portfolio. The company received an upfront payment of three million dollars from Akebia when it licensed the compound praliciguat and has since earned additional milestone payments as Akebia advances the drug through clinical testing. Cyclerion is eligible to receive further milestone sums and royalty payments that are tied to sales of praliciguat if it reaches the market. The firm also expects to obtain future payments from its collaboration with Medsteer and from the MIT license agreement should those programs progress. In addition Cyclerion has an effective shelf registration statement that allows it to access capital markets subject to market conditions. At present Cyclerion has no commercial product on the market and therefore does not collect product sales revenue.

Cyclerion occupies a niche within the broader psychiatric treatment landscape where it aims to differentiate its approach through a technology enabled delivery system for anesthetic agents. The most direct competitors for treatment resistant depression include Janssen with its product Spravato and Eli Lilly with Symbyax which are the only two pharmacotherapies approved in the United States for this indication. Other companies such as Compass Pathways and Axsome Therapeutics are investigating novel modalities including psychedelic compounds and rapid acting agents. Large pharmaceutical firms like Pfizer Novartis and AbbVie also have research programs targeting depression and related disorders. Cyclerion’s advantage lies in its use of generic anesthetic agents propofol and dexmedetomidine whose safety profiles are well established combined with a closed loop monitoring system that aims to individualize dosing. This strategy may allow the company to offer a treatment that can be administered in standard hospital settings without requiring entirely new drug substances. The firm believes that its combination of pharmacology and device technology could provide a differentiated option for patients who have not responded to conventional antidepressants.

The company’s current customers are primarily its licensing partners and collaborators. Akebia is the licensee for praliciguat and provides milestone payments as it progresses the drug through clinical trials. The Massachusetts Institute of Technology provides intellectual property under a license agreement and may receive royalties if CYC 126 succeeds. Medsteer is a collaborator that supplies technology and data assets for the closed loop system. Should CYC 126 receive regulatory approval the end users would be hospitals and patients suffering from treatment resistant depression who would receive the therapy in procedure rooms or post anesthesia care units. In addition Cyclerion may engage with health insurance providers and government payers to secure reimbursement for any future approved product. The firm also interacts with clinical investigators and academic medical centers that conduct the trials necessary to advance its programs.